Circulating cell-free DNA from colorectal cancer patients may reveal high KRAS or BRAF mutation load

Translational Oncology

Volumn 6, Issue 3, 2013, Pages 319-328

  Mouliere, Florent ^a,b,c,d,e   Messaoudi, Safia El ^a,b,c,d,e   Gongora, Celine ^a,b,c,d   Guedj, Anne Sophie ^e   Robert, Bruno ^a,b,c,d   del Rio, Maguy ^a,b,c,d   Molina, Franck ^g   Lamy, Pierre Jean ^f   Lopez Crapez, Evelyne ^f   Mathonnet, Muriel ^g   Ychou, Marc ^d   Pezet, Denis ^h   Thierry, Alain R ^a,b,c,d,g  

^a INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

^b INSERM   (France)

^c UNIV MONTPELLIER   (France)

^d CENTRE VAL D AURELLE   (France)

^e CNRS   (France)

^f Laboratoire de Biologie Specialisée et d'Oncogenetique   (France)

^g LIMOGES UNIVERSITY HOSPITAL   (France)

^h UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DNA; K RAS PROTEIN;

ALLELE; AMPLICON; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DNA EXTRACTION; DNA FRAGMENTATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; MUTATION; NONHUMAN; POINT MUTATION; POLYMERASE CHAIN REACTION; PYROSEQUENCING; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 84878734930     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.12445     Document Type: Article

References (31)

1. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi B, Louvet C, et al. (2008). KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26, 374-379.
2. Deng G, Bell I, Crawley S, Gum J, Terdiman JP, Allen BA, Truta B, Sleisenger MH, and Kim YS (2004). BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 10, 191-195.
3. Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, and Engelman JA (2010). BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal 3, ra84.
4. Lea A, Allingham-Hawkins D, and Levine S (2010). BRAF p. Val600Glu (V600E) testing for assessment of treatment options in metastatic colorectal cancer. PLoS Curr 2, RRN1187.
5. Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, and Beljanski M (1989). Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 46, 318-322.
6. Mead R, Duku M, Bhandari P, and Cree IA (2011). Circulating tumour markers can define patients with normal colons, benign polyps, and cancers. Br J Cancer 105, 239-245.
7. Kamat AA, Bischoff FZ, Dang D, Baldwin MF, Han LY, Lin YG, Merritt WM, Landen CN Jr, Lu C, Gershenson DM, et al. (2006). Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma. Cancer Biol Ther 5, 1369-1374.
8. Rago C, Huso DL, Diehl F, Karim B, Liu G, Papadopoulos N, Samuels Y, Velculescu VE, Vogelstein B, Kinzler KW, et al. (2007). Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. Cancer Res 67, 9364-9370.
9. Schwarzenbach H, Hoon DS, and Pantel K (2011). Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11, 426-437.
10. Gormally E, Hainaut P, Caboux E, Airoldi L, Autrup H, Malaveille C, Dunning A, Garte S, Matullo G, Overvad K, et al. (2004). Amount of DNA in plasma and cancer risk: a prospective study. Int J Cancer 111, 746-749.
11. Frattini M, Gallino G, Signoroni S, Balestra D, Lusa L, Battaglia L, Sozzi G, Bertario L, Leo E, Pilotti S, et al. (2008). Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. Cancer Lett 263, 170-181.
12. Leary RJ, Kinde I, Diehl F, Schmidt K, Clouser C, Duncan C, Antipova A, Lee C, McKernan K, De La Vega FM, et al. (2010). Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med 2, 20ra14.
13. Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, Diaz LA Jr, Goodman SN, David KA, Juhl H, et al. (2005). Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 102, 16368-16373.
14. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, et al. (2008). Circulating mutant DNA to assess tumor dynamics. Nat Med 14, 985-990.
15. Diehl F, Schmidt K, Durkee KH, Moore KJ, Goodman SN, Shuber AP, Kinzler KW, and Vogelstein B (2008). Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology 135, 489-498.
16. Holdhoff M, Schmidt K, Donehower R, and Diaz LA Jr (2009). Analysis of circulating tumor DNA to confirm somatic KRAS mutations. J Natl Cancer Inst 101, 1284-1285.
17. Thierry AR, Mouliere F, Gongora C, Ollier J, Robert B, Ychou M, Del Rio M, and Molina F (2010). Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res 38, 6159-6175.
18. Mouliere F, Robert B, Arnau Peyrotte E, Del Rio M, Ychou M, Molina F, Gongora C, and Thierry AR (2011). High fragmentation characterizes tumourderived circulating DNA. PLoS One 6, e23418.
19. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, et al. (2009). The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55, 611-622.
20. Morlan J, Baker J, and Sinicropi D (2009). Mutation detection by real-time PCR: a simple, robust and highly selective method. PLoS One 4, e4584.
21. Lopez-Crapez E, Mineur L, Emptas H, and Lamy PJ (2010). KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity? Br J Cancer 102, 1074-1075; author reply 1076-1077.
22. Schmidt K and Diehl F (2007). A blood-based DNA test for colorectal cancer screening. Discov Med 7, 7-12.
23. Soh J, Okumura N, Lockwood WW, Yamamoto H, Shigematsu H, Zhang W, Chari R, Shames DS, Tang X, MacAulay C, et al. (2009). Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS One 4, e7464.
24. Choi JJ, Reich CF III, and Pisetsky DS (2005). The role of macrophages in the in vitro generation of extracellular DNA from apoptotic and necrotic cells. Immunology 115, 55-62.
25. Ota DMand Drewinko B (1985). Growth kinetics of human colorectal carcinoma. Cancer Res 45, 2128-2131.
26. West NP, Dattani M, McShane P, Hutchins G, Grabsch J, Mueller W, Treanor D, Quirke P, and Grabsch H(2010). The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients. Br J Cancer 102, 1519-1523.
27. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, and Knippers R (2001). DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61, 1659-1665.
28. Deligezer U, Erten N, Akisik EE, and Dalay N (2006). Circulating fragmented nucleosomal DNA and caspase-3 mRNA in patients with lymphoma and myeloma. Exp Mol Pathol 80, 72-76.
29. Gahan PB and Stroun M (2010). The virtosome-a novel cytosolic informative entity and intercellular messenger. Cell Biochem Funct 28, 529-538.
30. Jung K, Fleischhacker M, and Rabien A (2010). Cell-free DNA in the blood as a solid tumor biomarker-a critical appraisal of the literature. Clin Chim Acta 411, 1611-1624.
31. Ellinger J, Wittkamp V, Albers P, Perabo FG, Mueller SC, von Ruecker A, and Bastian PJ (2009). Cell-free circulating DNA: diagnostic value in patients with testicular germ cell cancer. J Urol 181, 363-371.